Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP‐treated common marmoset

Basic fibroblast growth factor (bFGF) prevents damage to the nigrostriatal system in rodents. We now report the effects of bFGF administered by intraventricular infusion to adult common marmosets (Callithrix jacchus) previously rendered parkinsonian by the administration of 1‐methy‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Infusion commenced 10 weeks after MPTP treatment and the animals received bFGF in low (1.8 μg/l), medium (18 μg/l), or high (180 μg/l) doses over a 28‐day period. At weekly intervals, automated activity measurements, behavioral disability scoring, and videotape analyses were made. There was no improvement in the motor deficits exhibited by MPTP‐treated common marmosets receiving bFGF infusion compared to vehicle‐treated controls. Three of five high dose animals showed neurological impairment prior to the end of the study. No significant differences were found between control and bFGF‐infused MPTP‐treated common marmosets with respect to nigral tyrosine hydroxylase immunoreactive cell counts and striatal [3H]mazindol binding. All high dose animals showed hydrocephalus which was also observed in four other animals receiving bFGF. Histological examination revealed proliferation of the choroid plexus and ependyma which was most marked in the high dose animals. Adverse effects, in the form of hydrocephalus and neurological deterioration, were presumably secondary to an ependymal and choroid plexus reaction induced by bFGF. © 1996 Wiley‐Liss, Inc.

[1]  W. Pardridge Peptide drug delivery to the brain , 1991 .

[2]  K. Unsicker,et al.  Pharmacological effects of nerve growth factor and fibroblast growth factor applied to the transectioned sciatic nerve on neuron death in adult rat dorsal root ganglia , 1987, Neuroscience Letters.

[3]  M. Mattson,et al.  NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis , 1991, Neuron.

[4]  D. Gospodarowicz,et al.  Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. , 1986, Cell differentiation.

[5]  M. Frotscher,et al.  Basic fibroblast growth factor and nerve growth factor administered in gel foam rescue medial septal neurons after fimbria fornix transection , 1989, Journal of neuroscience research.

[6]  B. A. Brooks,et al.  Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys , 1986, Neuroscience.

[7]  A. Granholm,et al.  Delivery of Trophic Factors to the Primate Brain , 1993, Experimental Neurology.

[8]  J. Assouline,et al.  Rat astrocytes and Schwann cells in culture synthesize nerve growth factor-like neurite-promoting factors. , 1987, Brain research.

[9]  F. Gage,et al.  Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease , 1995, Nature Medicine.

[10]  Eugene M. Johnson,et al.  Fibroblast growth factor receptor‐bearing neurons in the CNS: Identification by receptor‐mediated retrograde transport , 1991, The Journal of comparative neurology.

[11]  H. Kimura,et al.  Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.

[12]  G. Ferrari,et al.  Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. , 1989, Developmental biology.

[13]  K. Fuxe,et al.  Basic FGF is present in dopaminergic neurons of the ventral midbrain of the rat. , 1991, Neuroreport.

[14]  S. Finklestein,et al.  Increased levels of basic fibroblast growth factor (bFGF) following focal brain injury. , 1990, Restorative neurology and neuroscience.

[15]  T. Crow,et al.  Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease? , 1986, Brain : a journal of neurology.

[16]  S. Fahn,et al.  Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats , 1991, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. DiFiglia,et al.  Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity , 1992, Brain Research.

[18]  P. Cuevas,et al.  Immunohistochemical localization of basic fibroblast growth factor in ependymal cells of the rat lateral and third ventricles. , 1991, Acta anatomica.

[19]  J. Cedarbaum,et al.  The Therapeutic Potential of Neurotrophic Factors in the Treatment of Parkinson's Disease , 1993, Experimental Neurology.

[20]  J. Blair‐West,et al.  Central action of basic fibroblast growth factor on ingestive behaviour in mice , 1995, Physiology & Behavior.

[21]  C. Cotman,et al.  Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo , 1988, Nature.

[22]  T. Hökfelt,et al.  Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Hefti,et al.  The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth FACTOR-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture , 1993, Neuroscience.

[24]  G. Ferrari,et al.  Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: Comparison with basic fibroblast growth factor , 1991, Journal of neuroscience research.